Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00448799 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
A Phase 1 study of Alzheimers Disease, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00448799: Completed Phase 1 study of Alzheimers Disease, sponsored by Molecular NeuroImaging.
NCT00448799 is a Phase 1 study of Alzheimers Disease that has completed, run by Molecular NeuroImaging. The registered enrollment target is 30 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00448799, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
Conditions Studied
Interventions
- RADIATION [123-I] AV-83 Injection and Imaging Procedures
Study Locations (1)
Connecticut
- Molecular NeuroImaging - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
What the finished NCT00448799 record still lists
NCT00448799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which [123-I] AV-83 Injection and Imaging Procedures is the first listed.
NCT00448799 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00448799 about?
NCT00448799 is a clinical study titled "Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls". The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
What is the current status of trial NCT00448799?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-03. Estimated completion is 2008-03.
What conditions does trial NCT00448799 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00448799?
The interventions under investigation include: [123-I] AV-83 Injection and Imaging Procedures (RADIATION).
Who is sponsoring clinical trial NCT00448799?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00448799 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00448799's enrollment target sits among peer trials
30 118th of 147 higher than 28 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia